EuHTA Impact on Innovations: Expectations and Challenges of EuHTA for Germany
Author(s)
Speakers: Lutz Herbarth, MBA, KKH Kaufmännische Krankenkasse, Hannover, Germany Julia Rumsch, LL.M., Federal Association of the Pharmaceutical Industry (BPI), Brussels, Belgium; Thomas Ecker, PhD, MA, Ecker + Ecker GmbH, Hamburg, Germany; Eva Susanne Susanne Dietrich, MD, Institute for Evidence-Based Positioning in the Healthcare Sector, Bonn, Germany
Presentation Documents
With the new EU HTA Regulation, the benefit assessment of new therapies is regulated for the first time at the European level. It regulates a joint clinical assessment of new medicinal products at European level, which is to start from January 2025 for the first products, including advanced therapy medicinal products (ATMPs) and oncology medicinal products (incl. orphan drugs). The framework is to be concretised. We want to discuss with several stakeholders from medical societies, health insurances and industry challenges and opportunities of EuHTA.
Sponsored by Kyowa Kirin GmbH
Conference/Value in Health Info
2023-11, ISPOR Europe 2023, Copenhagen, Denmark
Code
116
Topic
Health Technology Assessment